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Introduction
Proton pump inhibitors (PPIs) are the most widely
used agents for suppression of gastric acid in patients
with non-erosive gastroesophageal reflux disease
(GERD) and erosive esophagitis, accounting for over
$11 billion in US sales alone between brand name
and generic prescription formulations, whereas
approximately 80% of PPIs worldwide are now
purchased over-the-counter (1). Hundreds of clinical
trials studying PPIs summarised in the American
Gastroenterological Association and the American
College of Gastroenterology guidelines have demon-
strated superior clinical efficacy and safety in com-
parison with histamine-2 receptor antagonists
(H2RAs) (2,3). Since omeprazole was first released in
the early 1980s, there have been millions of favour-
able patient-years worth of experience with their use.
However, as all pharmacological agents (including
PPIs) have a risk of potential adverse effects, physi-
cians must weigh potential risks of long-term main-
tenance against therapeutic benefit. Metz and Yang
have summarised that the side effect profile of PPIs
includes rare idiosyncratic reactions (e.g. acute inter-
stitial nephritis) and metabolic interactions (espe-
cially hepatic cytochrome P450 effects), as well as
predictable pharmacological consequences of hypo-
or achlorhydria and reflex hypergastrinemia (4).
In recent years, dozens of retrospective epidemio-
logical studies examining a wide variety of potentially
associated adverse effects of PPIs have been pub-
lished. This review article will first describe the
pharmacological consequences of proton pump inhi-
bition, then discuss the trend of overutilisation of
PPIs in clinical practice and will conclude with a dis-
cussion of potential safety concerns in perspective
through a critical examination of the specific data
regarding these effects. The goal of this manuscript is
to demonstrate that PPIs should not be denied to
patients likely to benefit from them, yet the lowest
effective maintenance dose should be utilised and
such patients should be followed regularly to read-
dress the need for continued therapy.
Physiology of gastric acid secretion
Gastric acid is produced by both resting and meal-
stimulated parietal cells, following neurocrine, para-
crine, or endocrine stimulation by ligands, such as ace-
tylcholine, histamine or gastrin respectively, which
bind to their specific receptors on the basolateral sur-
face of the cell (4,5) (Figure 1). In turn, intracellular
second messenger systems are activated leading to
protein kinase formation and activation of H+ ⁄K+-
ATPase enzymes (proton pumps), which fuse with the
secretory canaliculus of the parietal cell resulting in
acid production, whereby intracellular hydrogen ions
are exchanged for extracellular potassium ions (5).
Once acid is produced, the lower luminal pH activates
a feedback mechanism to maintain appropriate
homeostatic control of acid secretion. This response is
mediated primarily by paracrine release of somato-
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statin from gastric antral and corpus D cells, which
inhibit G cell production of gastrin and enterochro-
maffin-like (ECL) cell production of histamine to
reverse the stimulus for acid production.
Pharmacology of proton pump
inhibition
Proton pump inhibitors inhibit the final common
pathway of gastric acid production, namely activated
H+ ⁄K+-ATPase enzymes, preventing the release of
hydrogen ions into the gastric lumen (4,6) (Figure 2).
They are pro-drugs that are absorbed into the circula-
tion and delivered to the gastric oxyntic mucosa,
where they concentrate in the secretory canaliculi of
parietal cells, where the pH is constitutively low. The
acidic microenvironment changes the PPI structure
allowing them to bind irreversibly with activated
H+ ⁄K+-ATPase enzymes, preventing hydrogen-potas-
sium exchange, leading to an elevation of gastric lumi-
nal pH which subsequently inhibits D cell release of
somatostatin, disinhibiting G cells and ECL-cells in an
attempt to restore acid secretory capability (4,6). As
PPIs concentrate 1000-fold greater than serum levels
in the secretory canaliculi, the resultant G cell release
of gastrin and ECL-cell release of histamine impedes
activation of additional proton pumps and gastric acid
secretion (4,6).
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Indications for long-term
(maintenance) PPI therapy
Antisecretory agents including PPIs and H2RAs are
commonly prescribed or used as short-term, self-
directed, over-the-counter (OTC) therapy for a
variety of upper gastrointestinal (UGI) symptoms,
without clinically significant pharmacological risks
(7). However, these agents are also indicated for
longer-term (maintenance) therapy of various acid-
peptic conditions including hypersecretory states,
such as Zollinger-Ellison syndrome or idiopathic hy-
persecretion, GERD and non-steroidal anti-inflam-
matory drug (NSAID) prophylaxis, all of which have
potentially severe morbidity and mortality that is sig-
nificantly ameliorated by PPI treatment (8–11). Stress
ulceration is an acid-peptic disorder, almost exclu-
sively seen in severely ill intensive care unit patients
that can be mitigated by maintenance antisecretory
therapy (AST) during the definable window of risk
(12,13). Despite clear indications for long-term PPI
therapy, many patients overutilise these medications
inappropriately without re-evaluation. Under such
conditions, a potential consequence of prolonged PPI
therapy is the potential for long-term hypergastrin-
emia, ECL-cell hyperplasia and parietal cell hypertro-
phy (4).
Physiological effects of prolonged PPI
inhibition
As PPIs bind directly to enzymes on the secretory
canaliculus of the parietal cell (7) rather than to
receptors on their basolateral surface (in contrast to
H2RAs), tachyphylaxis does not occur (4,14) (Fig-
ure 3). However, concern has been raised for years
regarding the potential for rebound gastric acid
hypersecretion, following PPI withdrawal (15–17).
Studies have demonstrated, symptomatic relapse
rates of 50–100% via an increasing trend in acid
secretory capability after PPI exposure (15,16),
whereas a systematic review of eight trials evaluating
rebound acid hypersecretion after discontinuation of
PPIs found that five short-term studies exhibited no
evidence for rebound hypersecretion and three
longer-term studies of greater than 8 weeks of PPI
exposure, demonstrated the presence of rebound
only in Helicobacter pylori-negative individuals (17).
Inadomi and colleagues examined the likelihood
of withdrawing PPI therapy treatment in patients
with UGI symptoms in two studies (18,19). In the
first study, the authors attempted to ‘step-down’
their patients from more than 8 weeks of PPI ther-
apy to H2RA therapy. Sixty per cent of patients were
able to step down and the only predictor of failure
to withdraw therapy was the presence or absence of
heartburn, suggesting that GERD patients were more
likely to be PPI-dependent than patients with other
foregut symptoms (18). In the second study, the
authors examined the potential for stepping down
therapy from twice daily to once daily PPI therapy.
Step-down was successful in nearly 80% of this
patient cohort, and the one predictor of success or
failure to step down to once daily drug was the dura-
tion of the prior PPI exposure (19). These data sup-
port the overall message of this manuscript in that
clinicians should strive to use the lowest effective
maintenance PPI dose.
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Recently, two trials in normal subjects examined
the potential for PPI withdrawal-induced rebound
gastric acid hypersecretion (20,21). The first study
was a double-blind, randomised, controlled trial of
120 normal volunteers given 8 weeks of esomepraz-
ole, followed by 4 weeks of placebo vs. 12 weeks of
placebo. Mean Gastrointestinal Symptom Rating
Scale (GSRS) scores were similar in both groups at
baseline, but rebounded after PPI withdrawal reach-
ing statistical significance over weeks 10–12 as com-
pared with individuals who received placebo for the
duration of the study (20). The presence of dyspep-
sia, heartburn or acid regurgitation was statistically
more frequent in the PPI withdrawal group over the
same period, and serum gastrin and chromogranin A
levels increased in the PPI group and then trended
down after withdrawal (20). A second study (21)
with similar design yielded similar results, although
the symptom rebound occurred sooner after PPI
withdrawal (by the 9th week) than in the previous
study. The latter study also examined meal-stimu-
lated gastrin levels and found that the area under the
gastrin curve increased significantly following PPI
therapy, but reverted to normal within a few weeks
of withdrawal (21).
To date, only one trial has examined the potential
for symptom rebound after PPI withdrawal in GERD
patients (22). Metz and colleagues conducted a post
hoc analysis of symptom recurrence and gastrin
trends in H. pylori-negative dexlansoprazole- or lan-
soprazole-exposed erosive esophagitis patients, who
rolled over into the placebo arms of the two double-
blind randomised, controlled dexlansoprazole main-
tenance registration trials, after healing over 4 or
8 weeks (23,24). This study is of interest because
dexlansoprazole may be more potent and has a
longer duration of action compared with other PPIs.
In this study of approximately 250 patients in each
arm there was no evidence for symptom rebound
(defined as more severe symptoms during follow-up
as compared with prior to diagnosis of erosive
esophagitis) or persistent hypergastrinemia in healed
erosive esophagitis patients who switched to placebo
maintenance therapy (22). Limitations of this study
include its post hoc design, the large number of (not
unexpected) dropouts during follow-up (because of
symptom relapse) and the short duration of PPI
exposure (albeit potent).
Reversibility of rebound
hypersecretion
To date, there have been no studies examining
whether rebound hypersecretion is reversible and if
so, how long it should take to occur. Studies of
gastrinoma patients who are cured surgically indicate
that it takes approximately 6 months for both basal
and maximal acid levels, and antisecretory dose
requirements to stabilise postoperatively (25). It
should be noted that gastrinoma patients are chroni-
cally hypergastrinemic with a mean delay in diagno-
sis of over 6 years, whereas H. pylori-negative PPI
recipients exhibit an exaggeration in gastrin response
primarily after meals (4).
Overutilisation of PPIs in clinical
practice
The concept of overutilisation of PPIs in clinical
practice has received significant attention in recent
years, relative to both the potential for adverse side
effects and preventable cost-expenditure. Studies
spanning over a decade have demonstrated that phy-
sicians in the US and UK, in both primary and spe-
cialty care, may overprescribe these medications
without re-evaluating patients for persistent clinical
indication (26–29). Cost-expenditure concerns have
led to the development of the step-down therapeutic
paradigm (18,19), and subsequent studies have
examined the indications for and duration of AST in
the outpatient setting (30–32). Similarly, studies have
evaluated the practise of stress ulcer prophylaxis
(SUP) in the non-intensive care unit (ICU) setting,
and have found significant non-judicial and prevent-
able overuse (33–35).
Ambulatory care setting
Many patients with GERD symptoms often begin
with a self-directed trial of OTC AST, whereas most
will consult their physician because of persistent
symptoms, or to obtain reimbursement for pre-
scribed AST. Physicians often leave patients on PPI
therapy indefinitely without readdressing: (i) if the
patient takes the PPI daily, (ii) if patient needs to
take the PPI daily to prevent symptoms, (iii) if the
patient has breakthrough or alarm symptoms sugges-
tive of advanced upper gastrointestinal disease or
(iv) if the patient can avoid symptoms without PPI
therapy (30).
A retrospective cohort study (30) conducted in a
Veterans’ Administration hospital evaluated both
indications for PPI therapy in the outpatient setting,
as well as follow-up parameters and cost-expenditure.
Across 946 patients, 35% were taking PPIs for an
appropriate indication, 13% for symptomatic relief,
19% for gastroprotection and 33% had no docu-
mented indication for PPI therapy. Appropriate use
of PPIs accounted for a mean duration of 1013 days,
while inappropriate use, defined as an absence of an
appropriate documented indication, accounted for a
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mean duration of 823 days. Nearly 49% of patients
across all four categories received PPIs without
re-evaluation, accounting for 1034 patient-years of
PPI use. The total cost of inappropriate PPI use was
estimated at $233,994 based on OTC PPI costs and
$1,566,252 based on average wholesale price (AWP)
costs.
A similar retrospective study (31) conducted on
168,727 managed care patients in Massachusetts
found that only 61% of subjects were taking PPIs for
an appropriate upper gastrointestinal diagnosis,
including GERD (38% of total) and dyspepsia (42%
of total). Approximately 39% of patients lacked
appropriate documentation for any UGI diagnosis;
almost 50% had documented symptoms of extra-
esophageal manifestations of potential UGI disease.
Nearly 19% of subjects had diagnoses or symptoms
commensurate with atypical GERD or dyspepsia,
whereas there was no subgroup analysis with regard
to defined gastroprotection with PPIs. The authors
did not assess preventable cost-expenditure in this
study.
Stress ulcer prophylaxis
According to the American Society of Health System
Pharmacists (ASHP) guidelines published in 1999
(13), SUP is not indicated in non-ICU patients with
fewer than two risk factors for clinically important
bleeding (e.g. head or thermal injury, hepatic or
renal transplantation, multiple trauma or spinal cord
injury, history of gastric ulceration 1 year prior to
admission, sepsis, ICU stay of greater than a week,
overt or occult bleeding for at least 6 days, or
chronic corticosteroid therapy). Despite these recom-
mendations, the evidence for prevention of stress
ulceration is poor, and the number needed to treat
[NNT] to prevent a single episode in the ICU setting
approaches 900 (36). There is no current evidence to
posit an NNT in the non-ICU setting.
A retrospective study (33) conducted in a univer-
sity hospital setting tested the hypothesis that many
patients admitted to general medical and family
medicine non-ICU services were routinely placed on
PPI therapy for SUP, when neither the admitting nor
the comorbid diagnoses support their use for either
treatment or gastrointestinal prophylaxis. The
authors also suspected that a large percentage of
patients started on a PPI for SUP at admission were
discharged from the hospital on a PPI, both rou-
tinely and randomly. The results showed that PPIs
were used for SUP in almost 90% of cases, with 22%
of all admitted patients receiving some form of SUP.
These findings were commensurate with previous
studies that found a 24–52% incidence of non-
indicated SUP (34,35).
Of 1769 patients in the university-based study
(33), there was not a single reported case of stress
ulceration. Of the 22% of patients started on a PPI
upon admission, 54% were discharged home on PPI
therapy and none had been re-evaluated within a
month to document necessity of therapy. Although
the most common admitting diagnoses for patients
in this study fell under the category of a GI aetiol-
ogy, only 15.6% of patients in this diagnostic cate-
gory received AST documented as SUP.
Rheumatological, renal and cardiac admitting diag-
noses were most likely to receive SUP with a PPI.
Extrapolated over 1 year, inappropriate PPI use
accounted for $44,096 in inpatient pharmacy costs
and $67,695 in outpatient pharmacy costs after dis-
charge, resulting in a total of $111,791 in preventable
expenditure.
PPI safety concerns
Safety concerns related to PPIs have centred on the
significant physiological changes induced by PPI
therapy, and the considerable risks of morbidity and
mortality associated with potential adverse effects.
A systematic review by Heidelbaugh and colleagues
(37), outlines the risk ratios of commonly associated
adverse events associated with PPI therapy (Table 1).
Despite the increasing attention to this issue, many
clinicians believe that the safety concerns associated
with PPI therapy, whether real or not, are irrelevant
in practise simply because the reported overall risk
estimates for many of the adverse effects were
modest.
Observational studies are susceptible to bias and
confounding. For example, although selection or
recall bias is generally not a major concern in popu-
lation-based studies using collected data, protopathic
bias (e.g. medications used to treat early signs of the
outcome of interest may appear to be associated with
the outcome) could have influenced the reported
association between PPI therapy and the risk of com-
munity-acquired pneumonia (38). Without randomi-
sation, observational studies cannot account for
unmeasured confounders. Information on many
potential confounders may not be readily available in
retrospective studies using medical records (e.g.
physical activity or OTC supplemental vitamin and
mineral intake).
Although all published studies on the association
between PPI therapy and hip fracture included
dementia as well as other potentially confounding
comorbidities as covariates, they may not be able to
adequately capture the gradation of these conditions
to fully account for the confounding effects, which
could lead to residual confounding. Thus, positive
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associations observed from these observational stud-
ies, particularly when the effect size is relatively mod-
est and the precise underlying mechanisms are
incompletely understood, cannot be taken as defini-
tive evidence supporting a causal relationship.
While it is obvious that the reported potential
adverse effects associated with PPI therapy are
important public health concerns (even at modest to
moderate magnitudes), what is unclear yet impera-
tive to consider is whether these potential associa-
tions are truly causal. As stated earlier, the strong
acid-suppressive effect of PPIs is maintained as long
as therapy is continued (39). In addition, the phar-
macodynamic interaction of PPIs with CYP2C19
P450 metabolism also appears to be a real phenome-
non (8,40,41).
Nearly all potential safety concerns of PPIs fall
into three major categories: (i) the direct effect of
gastric acid suppression itself (e.g. vitamin B12 defi-
ciency, community-acquired pneumonia, enteric
infections including Clostridium difficile-associated
diarrhoea [CDAD] and mineral malabsorption, lead-
ing to osteoporotic fracture), (ii) the physiological
response to the acid suppression (e.g. hypergastrin-
emia leading to increased cancer risk or hyperpara-
thyroidism and rebound hypersecretion after PPI
withdrawal) and (iii) the pharmacodynamic interac-
tion with the metabolism of other medications (e.g.
PPI and clopidogrel interaction). Overall, there is
sufficient biological plausibility to justify a careful
investigation to determine whether these theoretical
mechanistic connections translate into clinically
important adverse effects.
Almost the entire epidemiological evidence base
regarding the safety of PPI therapy to date is com-
posed of retrospective non-randomised trials. Post-
marketing surveillance is a critical part of drug safety
evaluation, as this mechanism generally consists of
spontaneous adverse event reporting systems (e.g.
Medwatch) and formal phase IV studies. Spontane-
ous reporting systems are inexpensive, vital for
hypothesis generation, but only rarely are they
sufficient for regulatory actions (e.g. PPI-associated
hypomagnesemia) (42). Although postmarketing
randomised controlled trial (RCT) data to inform
safety evaluations are occasionally available [e.g. the
COGENT trial for the PPI and clopidogrel interac-
tion (43), de novo dyspepsia after PPI withdrawal
(44,45)], observational studies involving large popu-
lations using existing medical records with extensive
person-years of drug use are the most common type
of studies conducted in this setting.
For some safety outcomes, observational studies
have shown either consistently no effect with PPI
therapy (e.g. colon cancer) (46–48) or highly con-
flicting results (e.g. community-acquired pneumonia)
(38,49,50). With other PPI safety outcomes (e.g.
osteoporotic hip fractures (51–60), CDAD (61–67),
interactions with clopidogrel (68–70), although the
majority of observational studies have reported an
overall positive association, inconsistencies remain
regarding the magnitude of risk increase as well as
the presence of dose- and ⁄or duration-response.
Recently, a case report highlighted six cases of
acute interstitial nephritis (AIN) associated with PPI
use, either by temporal association with kidney
injury or in response to cessation of PPI therapy
(71). The authors admit that the risk of AIN is likely
to be very low, a high index of suspicion for poten-
tial causality is needed and they hypothesise that if a
decline in renal function is observed then PPIs
should be stopped.
Future directions
Unless there are consistently negative observational
data [e.g. no observed increased risk of colorectal
cancer with short- or long-term PPI use (46)], it is
not a sensible approach to simply dismiss the poten-
tial risk of PPIs in the setting of suggestive and plau-
sible, yet methodologically limited epidemiological
evidence. The rational course of action should be to
pursue more definitive evidence through carefully
designed clinical research. Future studies should
move beyond simply looking at gross epidemiological
associations or generating often uninterpretable sum-
mary estimates from the invariably heterogeneous
pool of observational studies.
Preferred study designs would be either a prospec-
tive cohort design to allow better control of potential
confounders or, if possible, RCTs. Regarding the
issue of PPI-related fracture risk, a recent study from
Canada using bone mineral density (BMD) data is a
good example of such methodology (60). Although
this study was limited by the use of a crude BMD
assessment approach and the study cohort being a
convenience sample with an unusual risk profile for
osteoporosis (4), this study represents an important
step in the right direction. A current (non-published)
NIH-funded prospective cohort study is comparing
the volumetric BMD measured by peripheral quanti-
tative computed tomography (CT), between long-
term PPI users and non-users. This type of study can
address the primary methodological limitations
inherent to the existing observational studies, and
ultimately help unravel the nature of the observed
epidemiological link between PPI therapy and the
adverse effects. If a true causal association can be
confirmed, then such studies can also provide useful
information regarding potential preventive measures.
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Minimisation of risk from PPIs
While awaiting more definitive evidence, prescription
of PPI therapy in practise can be guided by several
general principles to minimise potential risks. First,
clinicians should only use PPI therapy in patients
who will clearly benefit from it. Importantly, no
patients with proper indications for PPI therapy
should be deprived of these highly effective medica-
tions. It is obvious from the existing evidence that
the most consistent and largest increase in the risk of
adverse effects is generally associated with long-term
and ⁄or high-dose PPI therapy. Therefore, in patients
with appropriate indications for PPI therapy, the
lowest effective dose should always be prescribed.
Unnecessary long-term and ⁄or continuous therapy
can be avoided by considering on-demand therapy in
suitable patients and conducting periodic review of
treatment indications (18,19).
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